Archive | Clinical Trials

Melanoma Vaccine from NeoVox Shows Anti-Tumor Response Four Years Later

In encouraging news regarding melanoma therapy, researchers found that a personalized vaccine continues to keep cancer cells in check four years after patients received it.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications

Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, Melanoma

Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma (HNSCC) and melanoma received the combination of eganelisib (IPI-549), a selective PI3K-? inhibitor, and nivolumab (Opdivo).

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications

Avastin Plus Chemotherapy Improves Progression-Free and Overall Survival in Mucosal Melanoma

Avastin (bevacizumab) with carboplatin plus paclitaxel improved overall survival (OS) and progression-free survival (PFS) compared with carboplatin and paclitaxel alone in patients with metastatic mucosal melanoma, according to findings from a phase 2 study published in the Journal of Clinical Oncology.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 combination study of IDE196 and crizotinib, a cMET inhibitor, in metastatic uveal melanoma (MUM).

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials